Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by uncontrolled complement activation and leading to thrombocytopenia, microangiopathic hemolysis acute kidney injury. Eculizumab, humanized monoclonal antibody that inhibits the cleavage protein C5, effectively reverses laboratory evidence TMA improves function in most patients with aHUS. Heredi...

INTRODUCTION Differential diagnosis of thrombotic microangiopathies can be difficult. Atypical hemolytic uremic syndrome is a rare, life-threatening disease caused by uncontrolled chronic activation of alternative complement pathway, resulting in microvascular thrombosis, organ ischemia and damage. Prognosis is poor: up to 65 percent of patients require dialysis or have kidney damage of varying...

F.E. von Eyben, PhD, MD, Klovervanget 22 a 11, DK-5000 Odense (Denmark) Dear Sir, Hemolytic-uremic syndrome comprises a triad of findings: acute microangiopathic hemolytic anemia, thrombocytopenia, and acute renal insufficiency [1]. In most cases of hemolytic-uremic syndrome in the adult the etiology is unknown, but a few cases have been reported as complications of typhoid fever [2], E. coli a...

1. Cutler C, KimHT, Ayanian S, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010;16:1180-1185. 2. Fakhouri F, Jablonski M, Lepercq J, et al. Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. Blood. 2008;112:4542-4545. 3. Kavanagh D, ...